17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Brenda Weigel, M.D

COG Phase I Consortium

Intervention

tanespimycin(drug)

Enrollment

36 enrolled

Eligibility

1-21 years · All sexes

Timeline

2004

Study locations (1)

• COG Phase I Consortium, Arcadia, California, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute undifferentiated leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06466395
  A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias
  M.D. Anderson Cancer Center

See all trials for Acute undifferentiated leukemia →